Quick Answer
vTv Therapeutics Inc. reported Revenue (ASC 606) of $0.00 for fiscal year 2025.
vTv Therapeutics Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $0.00 | -100.0% |
| 2024 | $1.02M | — |
| 2023 | $0.00 | -100.0% |
| 2022 | $2.02M | -49.6% |
| 2021 | $4.00M | -37.6% |
| 2020 | $6.41M | +132.1% |
| 2019 | $2.76M | -77.8% |
| 2018 | $12.43M | +4172.9% |
| 2017 | $291.0K | -54.1% |
| 2016 | $634.0K | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.00 | — | — |
| June 30, 2025 | $0.00 | — | — |
| March 31, 2025 | $0.00 | -100.0% | — |
| September 30, 2024 | $0.00 | — | — |
| June 30, 2024 | $0.00 | — | -100.0% |
| March 31, 2024 | $1.00M | — | — |
| September 30, 2023 | $0.00 | — | — |
| June 30, 2023 | $0.00 | -100.0% | — |
- vTv Therapeutics Inc. showed a decrease of -100.0% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2016–2025 period, vTv Therapeutics Inc.’s revenue (asc 606) has declined by 100.0% (from $634.0 thousand to $0.00).
- The most recent figure is from vTv Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: